Format

Send to

Choose Destination
Clin Infect Dis. 2008 May 1;46(9):1455-7. doi: 10.1086/587106.

Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation.

Author information

1
Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Abstract

This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet-resistant and ganciclovir-resistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication.

PMID:
18419454
DOI:
10.1086/587106
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center